Effect of a six-month vitamin D supplementation on depressive symptoms in patients with major depressive episode (DepFuD): a double-blinded randomised controlled trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

DepFuD was supported by Finnish State Research Funding (VTR).

Who Took Part

The age groups tagged for this paper are teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

Outpatients with mild to severe depression episode, aged 18-65 years, were included.

How the Study Was Run

The researchers set it up as a randomized, double-blind and parallel-group study.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

The Vitamin D, K2, Magnesium and Zinc group and the comparison group ran side by side rather than switching.

Data was collected in Finland between November 2015 and December 2020.

What Was Measured

Topics PubMed links to this paper include Dietary Supplements, Finland, Major Depressive Disorder, Psychiatric Status Rating Scales, Vitamin D and Vitamins.

Author keywords: Depression, Depressive symptoms, Intervention and Mental health.

What This Means in Plain Language

The paper is a randomized, double-blind and parallel-group study of Vitamin D, K2, Magnesium and Zinc.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (Journal of affective disorders), a journal based in Netherlands.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.